

1 **Aerobic exercise but not resistance exercise reduces intrahepatic lipid content and visceral**  
2 **fat and improves insulin sensitivity in obese adolescent girls: A randomized controlled trial**

3  
4 SoJung Lee, PhD <sup>1</sup>, Anthony R. Deldin, MS <sup>3</sup>, David White, MS <sup>3</sup>, YoonMyung Kim, PhD <sup>4</sup>,  
5 Ingrid Libman, MD PhD <sup>1,2</sup>, Michelle Rivera-Vega, MD <sup>1,2</sup>, Jennifer L. Kuk, PhD <sup>5</sup>, Sandra  
6 Sandoval, MD <sup>1</sup>, Chris Boesch, MD PhD <sup>6</sup>, Silva Arslanian, MD <sup>1,2</sup>

- 7  
8 1. Division of Weight Management and Wellness,  
9 2. Division of Pediatric Endocrinology, Metabolism and Diabetes Mellitus,  
10 Children's Hospital of Pittsburgh of UPMC,  
11 University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania 15224  
12 3. Department of Health and Physical Activity, School of Education,  
13 University of Pittsburgh, Pittsburgh, PA 15213  
14 4. University College, Yonsei University International Campus, Incheon, Korea  
15 5. School of Kinesiology and Health Science,  
16 York University, Toronto, Ontario, Canada M3J 1P3  
17 6. Department of Clinical Research/AMSM,  
18 University of Bern, Pavilion 52 Inselspital, Bern CH-3010, Switzerland

19  
20 **ClinicalTrials.gov Identifier:** NCT01323088

21 **Running head:** Reduction in Insulin Resistance with Exercise in Obese Girls

22 **Word count:** 3,488

23  
24  
25 *All correspondence and reprint requests addressed to:*

26  
27 SoJung Lee, Ph.D.  
28 Division of Weight Management and Wellness  
29 Children's Hospital of Pittsburgh  
30 University of Pittsburgh School of Medicine  
31 Faculty Pavilion Sixth Floor (Office 6102)  
32 400 45th Street, Pittsburgh, PA 15226  
33 Phone: (412) 692-5147  
34 Fax: (412) 692-8531  
35 E-mail: [SoJung.Lee@chp.edu](mailto:SoJung.Lee@chp.edu)

37 **ABSTRACT**

38 It is unclear whether regular exercise alone (no caloric restriction) is a useful strategy to reduce  
39 adiposity and obesity-related metabolic risk factors in obese girls. We examined the effects of  
40 aerobic (AE) versus resistance exercise (RE) alone on visceral adipose tissue (VAT), intrahepatic  
41 lipid and insulin sensitivity in obese girls. Forty-four obese adolescent girls (BMI  $\geq 95^{\text{th}}$ , 12-18  
42 yrs) with abdominal obesity (waist circumference  $106.5 \pm 11.1$  cm) were randomized to 3-  
43 months of 180 min/week AE ( $n=16$ ) or RE ( $n=16$ ) or a non-exercising control group ( $n=12$ ).  
44 Total fat and VAT were assessed by MRI and intrahepatic lipid by proton magnetic resonance  
45 spectroscopy. Intermuscular AT (IMAT) was measured by CT. Insulin sensitivity was  
46 evaluated by a 3-hour hyperinsulinemic ( $80 \text{ mU/m}^2/\text{min}$ )-euglycemic clamp.  
47 Compared with controls ( $0.13 \pm 1.10$  kg), Body weight did not change ( $P>0.1$ ) in the AE ( $-1.31$   
48  $\pm 1.43$  kg) and RE ( $-0.31 \pm 1.38$  kg) groups. Despite the absence of weight loss, total body fat  
49 (%) and IMAT decreased ( $P<0.05$ ) in both exercise groups compared with control. Compared  
50 with control, significant ( $P<0.05$ ) reductions in VAT ( $\Delta -15.68 \pm 7.64 \text{ cm}^2$ ) and intrahepatic lipid  
51 ( $\Delta -1.70 \pm 0.74\%$ ), and improvement in insulin sensitivity ( $\Delta 0.92 \pm 0.27 \text{ mg/kg/min per } \mu\text{U/ml}$ )  
52 were observed in the AE group, but not the RE group. Improvements in insulin sensitivity in the  
53 AE group were associated with the reductions in total AT mass ( $r = -0.65, P=0.02$ ). In obese  
54 adolescent girls, aerobic exercise, but not resistance exercise is effective in reducing liver fat,  
55 visceral adiposity and improving insulin sensitivity independent of weight loss or calorie  
56 restriction.

57 **Word count:** 240

58 **Key word:** insulin sensitivity, intrahepatic lipid, visceral fat, exercise, adolescents

59

60 **INTRODUCTION**

61           The epidemic rate of childhood obesity is a major health concern in the United States as  
62 overweight and obese youth are at increased risk of developing co-morbidities such as non-  
63 alcoholic fatty liver disease (35), type 2 diabetes (33) and metabolic syndrome (21, 41), once  
64 considered diseases of adulthood. Although both diet and physical activity are considered the  
65 first line of approach to treat obese youth (9), we recently reported that in obese adolescent boys  
66 increasing physical activity alone, independent of calorie restriction, is beneficial to reduce total  
67 fat, visceral adiposity and intrahepatic lipid, and improves cardiorespiratory fitness (CRF) (22).  
68 In obese adolescent girls, the utility of exercise alone as a strategy for reducing obesity-related  
69 metabolic risk factors is currently unclear. Given the lower physical activity levels in girls than  
70 in boys (14), and that physical activity declines substantially in girls during adolescence (17), we  
71 conducted a randomized controlled trial to examine the role of regular exercise alone (i.e. no  
72 calorie restriction) in reducing obesity-related risk factors in previously sedentary obese  
73 adolescent girls. Specifically, we compared the effects of aerobic (AE) versus resistance  
74 exercise (RE) on insulin sensitivity, visceral adipose tissue (VAT), and ectopic fat depositions in  
75 the liver and skeletal muscle.  
76

77 **MATERIALS AND METHODS**

78 *Subjects*

79           The study (ClinicalTrials.gov Identifier: NCT01323088) was conducted from August,  
80 2010 through October, 2012 at Children’s Hospital of Pittsburgh (CHP). Obese [BMI  $\geq$  95<sup>th</sup>  
81 percentile (30)] black and white girls were recruited via flyers posted in the city public  
82 transportation system and posters placed on campus, and from the Weight Management and  
83 Wellness Center at CHP. Inclusion criteria included that the subjects be 12-18 years of age,  
84 pubertal (Tanner Stages III-V), non-smokers, non-diabetic, and physically inactive (no  
85 participation in structured physical activity for the past three months except school physical  
86 education classes). Exclusion criteria included recent significant weight change (BMI  $>2$ -3  
87 kg/m<sup>2</sup>), musculo-skeletal injuries, endocrine disorders (e.g., polycystic ovary syndrome, type 2  
88 diabetes), syndromic obesity, pregnancy, psychiatric disorders and use of chronic medications  
89 that are known to influence glucose metabolism or body composition. Girls with oral or  
90 injectable contraceptives were also excluded. Participants self-identified as black or white. A  
91 complete medical history, physical examination and pubertal development were assessed  
92 according to Tanner criteria (37) by a certified nurse practitioner. The investigation was  
93 approved by the University of Pittsburgh Institutional Review Board. Parental informed consent  
94 and child assent were obtained from all participants before participation. All participants  
95 underwent routine hematological and biochemical tests at the Pediatric Clinical and Translational  
96 Research Center (PCTRC) at CHP.

97

98 *Randomization*

99 Randomization was performed after completing baseline evaluation. Similar to our  
100 previous study (22), random assignment to one of three interventions, AE, RE or a non-  
101 exercising control group was performed by lottery using a completely randomized design and  
102 cell sizes of 16.

103

#### 104 *Exercise regimen*

105 The exercise groups exercised at either the downtown Pittsburgh YMCA exercise facility  
106 or the exercise laboratory at CHP for 3 months. All exercise sessions were by appointment and  
107 supervised by exercise physiology graduate students. Participants in the AE group exercised  
108 three times per week, for 60 minutes/session (including 5 min warm-up and 5 min cool-down),  
109 using treadmills and/or ellipticals. AE programs progressively increased in duration and  
110 intensity, beginning at 40 min at ~50% of  $VO_{2peak}$ , increased up to 60 min at 60-75% of  $VO_{2peak}$   
111 by week two. Participants wore a heart rate monitor (Polar Oy, Kempele, Finland) during the  
112 exercise sessions to ensure achievement of the target heart rate. The heart rate range associated  
113 with 60-75% of  $VO_{2peak}$  was determined from the baseline maximal oxygen uptake test for each  
114 subject. Energy expenditure was estimated using the heart rate- $VO_2$  relationship observed  
115 during the  $VO_{2peak}$  test.

116 The RE group performed a series of 10 whole body exercises, three times per week, for  
117 60 minutes/session. Each training session included leg press, leg extension, leg flexion, chest  
118 press, latissimus pull down, seated row, bicep curl and tricep extension using stack weight  
119 equipment. In addition, a single set of push-ups and sit-ups were performed. For the first four  
120 weeks, participants performed 1-2 sets of 8-12 repetitions at 60% of baseline 1RM (repetition

121 maximum) with proper lifting techniques. During weeks 4 ~ 13, subjects performed 2 sets of 8-  
122 12 repetitions to fatigue.

123 Control subjects were asked not to participate in structured physical activities throughout  
124 the study. To maintain adherence, participants were given the opportunity to participate in  
125 exercise sessions following the completion of post-intervention evaluations.

126

### 127 *Dietary regimen*

128 All participants were asked to follow a weight maintenance diet (55-60% carbohydrate,  
129 15-20% protein, and 25-30% fat) throughout the study to be able to assess the effects of regular  
130 exercise alone on insulin sensitivity and fat distribution. Daily energy requirements to maintain  
131 baseline body weight were determined at baseline by estimating resting energy expenditure and  
132 multiplying the obtained value by a factor of 1.2 (12)

133

### 134 *Anthropometrics*

135 Body weight was measured to the nearest 0.1 kg and height was measured to the nearest  
136 0.1 cm. Waist circumference was measured at the top of the iliac crest and the average of two  
137 measurements was used in the analyses.

138

### 139 *Oral glucose tolerance test*

140 Participants reported to the PCTRC after an overnight fast for a 2-hour oral glucose  
141 tolerance test (OGTT, 1.75 g/kg, max 75 g). Blood samples were obtained at -15, 0, 15, 30, 60,  
142 90 and 120 minutes for determination of glucose and insulin levels. Glucose and insulin area

143 under the curve (AUC) was determined using a trapezoid model (2). Participants remained in the  
144 PCTRC and stayed overnight at CHP to undergo the euglycemic clamp test the next morning.

145

146 *Measurement of insulin sensitivity*

147 Fasting endogenous glucose production was measured with a primed (2.2  $\mu\text{mol/kg}$ )  
148 constant-rate infusion of [6, 6-<sup>2</sup>H<sub>2</sub>]glucose (Isotech, Miamisburg, OH) from 0730–0930 h as  
149 shown by us previously (4). Blood was sampled at the start of the stable isotope infusion (-120  
150 min) and every 10 min from -30 to 0 min (basal period) for determination of plasma glucose,  
151 insulin, and isotopic enrichment of glucose. Fasting hepatic glucose production (HGP) was  
152 calculated during the last 30 min. (-30 to time zero) of the basal 2-h infusion period. Fasting  
153 hepatic insulin sensitivity was calculated as the inverse of the product of hepatic glucose  
154 production and fasting plasma insulin concentration (1,000/HGP x fasting plasma insulin) as  
155 shown previously (4). After the 2-h baseline isotope infusion period, insulin-mediated glucose  
156 uptake and insulin sensitivity were measured during a 3-h hyperinsulinemic-euglycemic clamp  
157 from 0930-1230 h. Intravenous crystalline insulin (Humulin; Lilly Indianapolis, IN) was infused  
158 at a constant rate of 80 mU/m<sup>2</sup> per min, and plasma glucose was clamped at 5.6 mmol/l with a  
159 variable-rate infusion of 20% dextrose based on arterialized plasma glucose determinations every  
160 5 min. Peripheral insulin sensitivity was calculated by dividing insulin-stimulated glucose  
161 disposal rate by the steady-state plasma insulin concentration during the last 30 min of the clamp.  
162 In the exercise groups, post-exercise clamp test was performed 48-72 hours post-exercise session  
163 to control for the effects of acute exercise on glucose uptake (31). One subject in the aerobic  
164 group did not complete the post-intervention clamp due to difficulty with IV access. One control  
165 subject's post-intervention clamp test ended early due to IV issues and her glucose disposal rate

166 at 80 min was used to calculate insulin sensitivity. Among study completers ( $n=36$ ), 14 subjects  
167 and 19 subjects were examined in the luteal and follicular phase, respectively at baseline and 17  
168 subjects and 16 subjects were examined in the luteal and follicular phase, respectively at follow-  
169 up. The phase of the menstrual cycle was not determined in three subjects who had irregular  
170 menstrual cycle at both time points.

171

### 172 *Biochemical measurements*

173 Plasma glucose was measured by the glucose oxidase method with a glucose analyzer  
174 (YSI, Inc., Yellow Springs, OH), and the insulin concentration was determined by  
175 radioimmunoassay (3).

176

### 177 *Total adipose tissue (AT), skeletal muscle and abdominal AT*

178 Whole-body magnetic resonance imaging (MRI) was obtained with a 3.0 Tesla magnet  
179 (Siemens Medical Systems, Erlangen, Germany) using our standard protocol (25). One subject  
180 in the control group (post measurement) and in the AE group (both pre and post measurement)  
181 did not complete MRI and  $^1\text{H}$ -MRS due to claustrophobia.

182

### 183 *Intrahepatic lipid by proton magnetic resonance spectroscopy ( $^1\text{H}$ -MRS)*

184  $^1\text{H}$ -MRS was performed with a 3.0 Tesla MR system (Siemens, Tim Trio, Erlangen,  
185 Germany) using a body matrix coil and a spine matrix (Siemens, Erlangen, Germany) using our  
186 standard protocol (22). A voxel ( $30 \times 30 \times 20 \text{ mm}^3$ ) was placed avoiding blood vessels and  
187 intrahepatic bile ducts, using the following parameters (TR = 4000 ms, TE = 30 ms). Eight  
188 acquisitions were recorded in a measuring time of 32 sec without water suppression and the



189 average of eight spectra was used for intrahepatic lipid (%) calculation as shown below. Spectra  
190 were fitted using the AMARES algorithm in the Java-based magnetic resonance user interface  
191 (jMRUI) software package (28). Absolute concentrations of intrahepatic lipid (CH<sub>2</sub>) were  
192 obtained from the area under the curve of the methylene signals of lipids at 1.3 ppm, using tissue  
193 water content as an internal reference. One subject (AE)'s baseline data was excluded due to  
194 motion artifact.

$$\text{Intrahepatic lipid (\%)} = \frac{\text{lipid peak}}{\text{water peak} + \text{lipid peak}} \times 100$$

#### 198 *Intermuscular adipose tissue (IMAT) by computed tomography (CT)*

199 Mid-thigh CT images were obtained on a GE CTI-Helical Scanner (GE Medical Systems,  
200 Milwaukee, Wisconsin) using 170 mA, 120 kV, a 512 X 512 matrix, and 48-cm field of view  
201 using our standard protocol (23). IMAT area was defined as AT area beneath the fascia lata  
202 surrounding skeletal muscle and AT area between muscle bundles as shown previously (11).

#### 204 *Cardiorespiratory fitness (CRF) and muscular strength*

205 CRF was determined using a graded treadmill test with the use of standard open-circuit  
206 spirometry techniques (AEI Technologies, Pittsburgh) until volitional fatigue using our standard  
207 protocol (22). Muscular strength was assessed with a one-repetition maximum (1RM) test for  
208 the supine chest press and seated leg press using weight stack equipment (Life fitness, Schiller  
209 Park, IL). Muscular strength index was calculated as the sum of the 1RM scores for the chest  
210 and leg press expressed per kg of body weight (16).

211

212 *Statistical Analysis*

213           A one-way analysis of variance (ANOVA) and ANCOVA adjusting for BMI and race  
214 were performed to examine group differences at baseline. When the ANOVA *P*-value was <0.05,  
215 a Tukey's post hoc comparison test was used to locate group differences. We examined the  
216 effect of the intervention using an intent-to-treat analysis for only randomized subjects with  
217 baseline data. Missing follow-up data values were estimated using multiple-imputations  
218 procedure (Proc MI) with 100 imputations (27). Repeated measures analysis of covariance was  
219 used to determine treatment change differences for each variable using the imputed data with  
220 adjustment for baseline values for that variable. We also examined the effect of the exercise  
221 intervention using as-treated analyses in participants who had complete baseline and follow-up  
222 data. Least squared means difference post hoc tests were used to determine differences between  
223 the control and intervention groups. The relationships between changes in total and abdominal  
224 fat, and insulin sensitivity were evaluated by Pearson correlations coefficients.

225           *P* values of less than 0.05 were accepted to indicate statistical significance. All analyses  
226 were performed using commercially available software (SAS, version 9.2; SAS Institute Inc,  
227 Cary, North Carolina). Unless otherwise indicated, data are expressed as mean (SE).

228

229 **RESULTS**

230 *Baseline characteristics*

231 Baseline subject characteristics are shown in **Table 1**. Fasting insulin,  
232 insulin AUC, insulin sensitivity and  $VO_{2peak}$  were lower ( $P<0.05$ ) in the RE group compared  
233 with the AE group. However, these differences did not remain significant ( $P>0.05$ ) after  
234 adjusting for BMI and race.

235

236 *Adherence to the exercise programs*

237 Of the 44 obese girls randomized, 37 completed their assigned treatment (**Figure 1**). We  
238 excluded one control subject from data analyses who was dissatisfied with the group assignment  
239 and was intentionally reducing calorie intake during the study. Average ( $\pm$  SD) attendance at the  
240 exercise sessions was 95% ( $\pm$  4.3%) in the AE and 97% ( $\pm$  2.8%) in the RE groups and average  
241 exercise duration was similar between the AE ( $56.0 \pm 1.1$  minutes/session) and RE ( $57.0 \pm 0.7$   
242 minutes /session) group. In the AE group, the average heart rate was  $153.0 \pm 6.6$  bpm and energy  
243 expenditure was  $536.6 \pm 72.9$  kcal/session.

244

245 *Changes in CRF and muscular strength*

246 Compared with the non-exercising control group, CRF increased ( $P<0.05$ ) by 17 % in the  
247 AE group, but not in the RE group (**Table 2**). Muscular strength increased ( $P<0.05$ ) in the RE  
248 group (45%) only by comparison to controls.

249

250 *Changes in total adiposity and skeletal muscle*

251 Body weight, BMI and waist circumference did not change ( $P>0.1$  for all) in either  
252 exercise groups (**Table 2**). Compared with controls, a significant reduction ( $P<0.05$ ) in % body  
253 fat was observed within the AE ( $-1.70 \pm 0.85\%$ ) and RE ( $-1.63 \pm 0.78\%$ ) groups. Skeletal muscle  
254 mass did not change within any of the exercise groups ( $P>0.05$ ).

255

#### 256 *Changes in VAT, intrahepatic lipid and IMAT*

257 Compared with controls, significant ( $P<0.05$ ) reductions in VAT ( $\Delta -15.68 \pm 7.64 \text{ cm}^2$ )  
258 and intrahepatic lipid ( $\Delta -1.70 \pm 0.74\%$ ) were observed in the AE, but not in the RE group  
259 (**Table 2**). In both AE ( $\Delta -13.5 \pm 4.2 \text{ cm}^2$ ) and RE ( $\Delta -10.9 \pm 4.2 \text{ cm}^2$ ) groups, there were  
260 reductions ( $P<0.05$ ) in IMAT by comparison to controls.

261

#### 262 *Changes in insulin sensitivity*

263 Compared with controls, fasting glucose production and hepatic insulin sensitivity did not  
264 change significantly in the AE and the RE groups (**Table 3**). Peripheral insulin sensitivity  
265 improved significantly in the AE group ( $0.92 \pm 0.27 \text{ mg/kg/min per } \mu\text{U/ml}$ ,  $P=0.0007$ ), even  
266 when insulin sensitivity was expressed per unit of FFM ( $\Delta 1.43 \pm 0.44 \text{ mg/kg FFM/min per}$   
267  $\mu\text{U/ml}$ ,  $P=0.001$ ), compared with controls ( $\Delta -0.79 \pm 0.35 \text{ mg/kgFFM/min per } \mu\text{U/ml}$ ). These  
268 observations remained unchanged when analyses were repeated excluding a control subject  
269 whose post-intervention clamp ended early due to IV issues. The improvement in peripheral  
270 insulin sensitivity in the AE group was significantly associated with the loss in total AT mass ( $r$   
271  $= -0.65$ ,  $P=0.02$ ), but not VAT or intrahepatic lipid ( $P>0.05$ ). No significant changes in OGTT  
272 parameters (such as glucose and insulin levels at 2 hr, and glucose and insulin AUCs) were  
273 observed in any groups.

274

275 **DISCUSSION**

276           The present investigation reveals that in obese adolescent girls, despite the absence of  
277 weight loss, significant reductions in percent body fat and IMAT were achieved after 3 months  
278 (3 days/weeks) of AE and RE programs. Moreover, AE but not RE was associated with  
279 significant reductions in visceral adiposity and intrahepatic lipid, and improvements in insulin  
280 sensitivity and CRF. These findings suggest, for the first time, that AE may be a better mode of  
281 exercise than resistance exercise in obese adolescent girls to reduce abdominal adiposity and  
282 liver fat, and improve insulin resistance.

283           Although adult studies report the beneficial effects of exercise alone on insulin action in  
284 women (8, 32, 34), little information is available regarding the independent role of regular  
285 exercise on insulin resistance in adolescent girls. Treuth et al. (38) reported no significant  
286 changes in fasting glucose and insulin, and glucose and insulin AUC in response to a 5-month  
287 strength training (3 days/week, 20 min/session) in obese prepubertal girls ( $n=9$ ). By contrast,  
288 Nassis et al. (29) demonstrated that 12 weeks of AE without weight loss (3 days/week, 40  
289 minutes/session) resulted in a significant reduction in insulin AUC (23%) in overweight and  
290 obese girls (9-15 years,  $n=19$ ). Using a randomized controlled trial, our findings that AE without  
291 calorie restriction and weight loss resulted in significant improvements in insulin sensitivity  
292 (33%), assessed by a 3-hr hyperinsulinemic-euglycemic clamp technique, extends previous  
293 observations (29, 38) using surrogate measures of insulin sensitivity (OGTT) and provides  
294 evidence that engaging in AE alone is an effective means of improving insulin sensitivity in  
295 these high risk obese adolescent girls. Additionally, the use of whole-body MRI, <sup>1</sup>H-MRS and  
296 computed tomography in our study allowed direct assessments of changes in whole-body adipose  
297 tissue distribution in response to aerobic exercise versus resistance exercise.

298 Our findings that AE without calorie restriction is associated with significant reductions  
299 in intrahepatic lipid and VAT in obese adolescent girls are consistent with van der Heijden et al.  
300 (39) who reported that a 12-week AE without calorie restriction (2 days/week, 30 min/session)  
301 was associated with reductions in intrahepatic lipid (~37%) and VAT (~9.3%) in a mixed sample  
302 of Hispanic obese boys and girls ( $n=15$ ). The current findings with respect to AE are paralleled  
303 with our previous observations in obese adolescent boys (22), who showed significant reductions  
304 in VAT (7%) and intrahepatic lipid content (40%). However, with respect to RE, the two  
305 genders responded differently. Unlike the obese adolescent boys (22), obese girls did not have  
306 significant reductions in intrahepatic lipid and VAT in response to RE. Further, unlike the obese  
307 adolescent boys (22), we did not find a significant increase in skeletal muscle mass in obese  
308 adolescent girls in response to resistance exercise. We are unclear about this observed gender  
309 difference in response to resistance exercise as the exercise training regimens and the  
310 methodologies ( $^1\text{H}$ -MRS and MRI) were identical in both studies. Perhaps, testosterone in  
311 adolescent boys may enhance the benefits of resistance exercise on skeletal muscle mass.

312 It is well-established that visceral fat is a strong risk factor for obesity related co-  
313 morbidities in youth (24, 40). Although the underlying mechanisms by which visceral fat is  
314 associated with metabolic abnormalities are unclear, it has been hypothesized that excess free  
315 fatty acids released from the visceral adipocytes drains directly into the liver via the portal vein,  
316 resulting in intrahepatic lipid accumulation, VLDL production and reduced insulin clearance in  
317 the liver (“the portal theory”) (5). However, in this study, visceral fat and intrahepatic lipid were  
318 not associated with both hepatic and peripheral insulin sensitivity in obese adolescent girls.  
319 These are different from our previous findings in obese adolescent boys (22), demonstrating that  
320 the change in insulin sensitivity was significantly correlated with the corresponding changes in

321 visceral fat ( $r = -0.47$ ,  $P < 0.05$ ). Perhaps, gender differences in the amount of visceral fat (lower  
322 visceral fat in obese girls vs. obese boys) may explain the strength of the relationships between  
323 visceral fat and insulin sensitivity in obese boys vs. obese girls.

324         There were also gender differences with respect to the change in peripheral insulin  
325 sensitivity after the exercise training program. While we observed significant improvements in  
326 insulin sensitivity in response to RE in obese adolescent boys (22), the identical RE intervention  
327 did not result in improvements in insulin sensitivity in obese adolescent girls. Theoretically, one  
328 would expect that cardiometabolic and diabetes risk factors would improve after resistance  
329 training. Contrary to the latter, Kirwan (19) showed that eccentric exercise resulted in transient  
330 decreases in insulin sensitivity (-37%) in healthy individuals that persists for ~48 h after the  
331 exercise bout. It has been suggested that the reductions in insulin sensitivity after eccentric  
332 exercise is mediated by increased inflammatory markers related to exercise-induced muscle  
333 damage (18). However, as we acquired insulin sensitivity measures with identical protocols in  
334 boys and girls, this is unlikely to explain the observed gender contrast in insulin sensitivity  
335 following the two different exercise regimens. Alternatively, others report substantial inter-  
336 individual variability in the ability to improve health outcomes in response to regular  
337 exercise. For example, Bouchard et al. (6) reported that among study completers ( $n = 1,687$ ) from  
338 six-exercise intervention trials (HERITAGE family study, DREW, INFLAME, STRRIDE,  
339 MARYLAND and JYVASKYLA), 8.4% had adverse changes in fasting insulin, 13.3% for  
340 HDL-C and 12.2% for systolic blood pressure after AE independent of age and CRF. It is  
341 unknown the degree to which this inter-individual variation in RE response occurs. Furthermore,  
342 the possibility that the two sexes may respond differently to various exercise regimens points to  
343 the need to individualize the exercise training to gain the most health benefit.

344 Our finding that both AE and RE is associated with reductions in IMAT in obese  
345 adolescent girls is of importance given that IMAT is inversely associated with insulin sensitivity  
346 in adolescents (23). That regular exercise is effective in reducing IMAT in obese girls is  
347 consistent with adult studies (13, 26), demonstrating the beneficial effects of exercise in reducing  
348 skeletal muscle lipid content measured by CT. However, these observations differ from studies  
349 employing <sup>1</sup>H-MRS, which report no significant changes in intramyocellular lipid (IMCL) in  
350 response to regular exercise in obese adolescents (22, 39) and obese adults (15). Although both  
351 CT and <sup>1</sup>H-MRS methods have been used in clinical research for assessing skeletal muscle lipid  
352 *in vivo*, it is important to note that IMAT measured by CT and IMCL measured by <sup>1</sup>H-MRS do  
353 not equate. Although CT is unable to differentiate between IMCL and extramyocellular lipids  
354 (EMCL), it measures a larger muscle group and muscle attenuation measured by CT as an  
355 overall lipid marker is more reproducible than EMCL or IMCL measured separately by <sup>1</sup>H-MRS  
356 (20).

357 Similar to our previous study in obese boys (22), obese adolescent girls complied well  
358 with the prescribed exercise training regimen resulting in high attendance rates. However,  
359 anecdotally, the girls in the RE group did not enjoy the treatment intervention as much as the AE  
360 group. Interestingly, this was the opposite sentiment given by obese boys. Therefore, given the  
361 superior improvements in metabolic health with aerobic exercise and the enjoyment factor, we  
362 propose that AE may be a better mode of exercise for adolescent girls of this age group.

363 The current physical activity guidelines from the U.S. Department of Health and Human  
364 Services (2008) suggest that youth should engage in both aerobic and muscle strengthening  
365 exercise to improve overall health (1). Indeed, randomized controlled studies in adults  
366 demonstrate that the combination of AE and RE is a better exercise strategy than either exercise



367 modality alone to improve glycemic control (7, 36) or insulin sensitivity (10). However, in  
368 children and adolescents it is currently unknown whether a combined AE and RE program would  
369 be associated with greater improvements in insulin sensitivity than either exercise alone and  
370 whether the response would be similar in boys and girls. Further investigations should shed light  
371 on this.

372           Limitations of this study warrant mention. Given the set length of intervention and the  
373 acute effects of exercise on insulin sensitivity, we were unable to measure insulin sensitivity  
374 during the same menstrual cycle before and after the intervention, which was true for all three  
375 groups. Our findings are limited to obese healthy black and white adolescent girls. Whether our  
376 findings would remain true in other racial groups, prepubertal girls and girls with oral or  
377 injectable contraceptives or girls with type 2 diabetes are unknown. Although we randomly  
378 assigned participants to intervention groups, this does not always result in similar characteristics  
379 between groups. Indeed, at randomization subjects in the RE group tended to have higher %  
380 body fat and lower insulin sensitivity compared with those in the AE group. As treatment  
381 changes are often related to the baseline value (i.e. poorer baseline values allow for a potentially  
382 larger improvement), we adjusted all analyses examining treatment effects for that corresponding  
383 baseline value. However, due to the small sample size in this study, we did not simultaneously  
384 adjust for all group baseline differences as this may limit our power and potentially be an over-  
385 adjustment as many of the health and obesity markers are inter-correlated. Although,  
386 participants were asked to log their energy intake during the study, this was completed by very  
387 few participants, and was generally done poorly.

388           In summary, the results of this study suggest that in previously sedentary, obese  
389 adolescent girls both aerobic and resistance exercise (3 days/weeks, ~180 min/week), without

390 calorie restriction and weight loss, is associated with reductions in total fat and IMAT. However,  
391 only aerobic exercise and not resistance exercise is associated with reductions in visceral  
392 adiposity and liver fat and improvement in insulin sensitivity, a major risk factor for type 2  
393 diabetes in youth.

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413 **ACKNOWLEDGMENTS**

414 The authors express their gratitude to the study participants and their parents, to Nancy Guerra  
415 (Certified Registered Nurse Practitioner), Jacqueline Washington (Research coordinator), Resa  
416 Stauffer (Laboratory research technician), the PCTRC nursing staff and the YMCA of Greater  
417 Pittsburgh for donating their exercise facilities.

The authors' contributions were as follows. Lee designed the study, obtained funding, researched data and wrote manuscript. Deldin, White and Kim trained research participants, analyzed MRI data and performed exercise testing. Libman, Rivera-Vega and Sandoval researched data and reviewed manuscript. Kuk performed statistical analyses and provided critical revision of the manuscript. Boesch assisted MRS data analyses and acquisition and reviewed manuscript. Arslanian provided funding, laboratory analyses and critical revision of the manuscript. Lee is the guarantor of this work, had full access to all the data and takes full responsibility for the integrity of data and the accuracy of data analysis.

418  
419  
420  
421  
422  
423  
424  
425  
426

427 **GRANTS**

428 This research was supported by the National Institutes of Health Grants 1R21DK083654-01A1,  
429 UL1 RR024153 and 2K24-HD-01357, Cochrane-Weber Foundation, Renziehausen Fund and  
430 Richard L. Day Endowed Chair.

431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468

469 **DISCLOSURES**

470

471 All authors have no conflicts of interest to declare.

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493 **REFERENCES**

- 494 1. **U.S. Department of Health and Human Services:** 2008 Physical Activity Guidelines  
495 for Americans (available at: [www.health.gov/paguidelines](http://www.health.gov/paguidelines)). Washington, DC: ODPHP  
496 Publication No U0036; 2008.
- 497 2. **Allison DB, Paultre F, Maggio C, Mezzitis N, and Pi-Sunyer FX.** The use of areas  
498 under curves in diabetes research. *Diabetes Care* 18: 245-250, 1995.
- 499 3. **Arslanian SA, Saad R, Lewy V, Danadian K, and Janosky J.** Hyperinsulinemia in  
500 african-american children: decreased insulin clearance and increased insulin secretion and its  
501 relationship to insulin sensitivity. *Diabetes* 51: 3014-3019, 2002.
- 502 4. **Bacha F, Saad R, Gungor N, and Arslanian SA.** Adiponectin in youth: relationship to  
503 visceral adiposity, insulin sensitivity, and beta-cell function. *Diabetes Care* 27: 547-552, 2004.
- 504 5. **Bjorntorp P.** "Portal" Adipose tissue as a generator of risk factors for cardiovascular  
505 disease and diabetes. *Arteriosclerosis* 10: 493-496, 1990.
- 506 6. **Bouchard C, Blair SN, Church TS, Earnest CP, Hagberg JM, Hakkinen K, Jenkins  
507 NT, Karavirta L, Kraus WE, Leon AS, Rao DC, Sarzynski MA, Skinner JS, Slentz CA,  
508 and Rankinen T.** Adverse metabolic response to regular exercise: is it a rare or common  
509 occurrence? *PLoS One* 7: e37887, 2012.
- 510 7. **Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, Mikus CR,  
511 Myers V, Nauta M, Rodarte RQ, Sparks L, Thompson A, and Earnest CP.** Effects of  
512 aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a  
513 randomized controlled trial. *JAMA* 304: 2253-2262, 2010.
- 514 8. **Cuff DJ, Meneilly GS, Martin A, Ignaszewski A, Tildesley HD, and Frohlich JJ.**  
515 Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. *Diabetes  
516 Care* 26: 2977-2982, 2003.
- 517 9. **Daniels SR, Jacobson MS, McCrindle BW, Eckel RH, and Sanner BM.** American  
518 Heart Association Childhood Obesity Research Summit: executive summary. *Circulation* 119:  
519 2114-2123, 2009.
- 520 10. **Davidson LE, Hudson R, Kilpatrick K, Kuk JL, McMillan K, Janiszewski PM, Lee  
521 S, Lam M, and Ross R.** Effects of exercise modality on insulin resistance and functional  
522 limitation in older adults: a randomized controlled trial. *Arch Intern Med* 169: 122-131, 2009.
- 523 11. **Goodpaster BH, Thaete FL, and Kelley DE.** Thigh adipose tissue distribution is  
524 associated with insulin resistance in obesity and in type 2 diabetes mellitus. *The American  
525 journal of clinical nutrition* 71: 885-892, 2000.
- 526 12. **Harris JA, and Benedict FF.** *A Biometric Study of Basal Metabolism in Man.*  
527 Washington DC: Carnegie Institution of Washington, 1919.
- 528 13. **Hutchison SK, Teede HJ, Rachon D, Harrison CL, Strauss BJ, and Stepto NK.**  
529 Effect of exercise training on insulin sensitivity, mitochondria and computed tomography muscle  
530 attenuation in overweight women with and without polycystic ovary syndrome. *Diabetologia* 55:  
531 1424-1434, 2012.
- 532 14. **Imperatore G, Cheng YJ, Williams DE, Fulton J, and Gregg EW.** Physical activity,  
533 cardiovascular fitness, and insulin sensitivity among U.S. adolescents: the National Health and  
534 Nutrition Examination Survey, 1999-2002. *Diabetes Care* 29: 1567-1572, 2006.
- 535 15. **Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW,  
536 and George J.** Aerobic exercise training reduces hepatic and visceral lipids in obese individuals  
537 without weight loss. *Hepatology* 50: 1105-1112, 2009.

- 538 16. **Jurca R, Lamonte MJ, Church TS, Earnest CP, Fitzgerald SJ, Barlow CE, Jordan**  
539 **AN, Kampert JB, and Blair SN.** Associations of muscle strength and fitness with metabolic  
540 syndrome in men. *Med Sci Sports Exerc* 36: 1301-1307, 2004.
- 541 17. **Kimm SYS, Glynn NW, Kriska AM, Barton BA, Kronsberg SS, Daniels SR,**  
542 **Crawford PB, Sabry ZI, and Liu K.** Decline in Physical Activity in Black Girls and White  
543 Girls during Adolescence. *N Engl J Med* 347: 709-715, 2002.
- 544 18. **Kirwan JP, and del Aguila LF.** Insulin signalling, exercise and cellular integrity.  
545 *Biochem Soc Trans* 31: 1281-1285, 2003.
- 546 19. **Kirwan JP, Hickner RC, Yarasheski KE, Kohrt WM, Wiethop BV, and Holloszy JO.**  
547 Eccentric exercise induces transient insulin resistance in healthy individuals. *J Appl Physiol* 72:  
548 2197-2202, 1992.
- 549 20. **Larson-Meyer DE, Smith SR, Heilbronn LK, Kelley DE, Ravussin E, and**  
550 **Newcomer BR.** Muscle-associated triglyceride measured by computed tomography and  
551 magnetic resonance spectroscopy. *Obesity (Silver Spring)* 14: 73-87, 2006.
- 552 21. **Lee S, Bacha F, Gungor N, and Arslanian S.** Comparison of different definitions of  
553 pediatric metabolic syndrome: relation to abdominal adiposity, insulin resistance, adiponectin,  
554 and inflammatory biomarkers. *The Journal of pediatrics* 152: 177-184, 2008.
- 555 22. **Lee S, Bacha F, Hannon T, Kuk JL, Boesch C, and Arslanian S.** Effects of aerobic  
556 versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and  
557 insulin sensitivity in obese adolescent boys: a randomized, controlled trial. *Diabetes* 61: 2787-  
558 2795, 2012.
- 559 23. **Lee S, Guerra N, and Arslanian S.** Skeletal muscle lipid content and insulin sensitivity  
560 in black versus white obese adolescents: is there a race differential? *The Journal of clinical*  
561 *endocrinology and metabolism* 95: 2426-2432, 2010.
- 562 24. **Lee S, Gungor N, Bacha F, and Arslanian S.** Insulin resistance: link to the components  
563 of the metabolic syndrome and biomarkers of endothelial dysfunction in youth. *Diabetes Care*  
564 dc07-0203, 2007.
- 565 25. **Lee S, Kim Y, Kuk JL, Boada FE, and Arslanian S.** Whole-body MRI and ethnic  
566 differences in adipose tissue and skeletal muscle distribution in overweight black and white  
567 adolescent boys. *J Obes* 2011: 159373, 2011.
- 568 26. **Lee S, Kuk JL, Davidson LE, Hudson R, Kilpatrick K, Graham TE, and Ross R.**  
569 Exercise without weight loss is an effective strategy for obesity reduction in obese individuals  
570 with and without Type 2 diabetes. *J Appl Physiol* 99: 1220-1225, 2005.
- 571 27. **Ratitch B and O'Kelly M.** Implementation of Pattern-Mixture Models Using Standard  
572 SAS/STAT Procedures. . *PharmaSUG Paper-SP04*, 2011.
- 573 28. **Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, and**  
574 **Graveron-Demilly D.** Java-based graphical user interface for the MRUI quantitation package.  
575 *Magma* 12: 141-152, 2001.
- 576 29. **Nassis GP, Papantakou K, Skenderi K, Triandafillopoulou M, Kavouras SA,**  
577 **Yannakoulia M, Chrousos GP, and Sidossis LS.** Aerobic exercise training improves insulin  
578 sensitivity without changes in body weight, body fat, adiponectin, and inflammatory markers in  
579 overweight and obese girls. *Metabolism* 54: 1472-1479, 2005.
- 580 30. **Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn**  
581 **LM, Curtin LR, Roche AF, and Johnson CL.** Centers for Disease Control and Prevention  
582 2000 growth charts for the United States: improvements to the 1977 National Center for Health  
583 Statistics version. *Pediatrics* 109: 45-60, 2002.

- 584 31. **Perseghin G, Price TB, Petersen KF, Roden M, Cline GW, Gerow K, Rothman DL,**  
585 **and Shulman GI.** Increased glucose transport-phosphorylation and muscle glycogen synthesis  
586 after exercise training in insulin-resistant subjects. *N Engl J Med* 335: 1357-1362, 1996.
- 587 32. **Poehlman ET, Dvorak RV, DeNino WF, Brochu M, and Ades PA.** Effects of  
588 resistance training and endurance training on insulin sensitivity in nonobese, young women: a  
589 controlled randomized trial. *The Journal of clinical endocrinology and metabolism* 85: 2463-  
590 2468, 2000.
- 591 33. **Rosenbloom AL, Joe JR, Young RS, and Winter WE.** Emerging epidemic of type 2  
592 diabetes in youth. *Diabetes Care* 22: 345-354, 1999.
- 593 34. **Ryan AS, Pratley RE, Goldberg AP, and Elahi D.** Resistive training increases insulin  
594 action in postmenopausal women. *J Gerontol A Biol Sci Med Sci* 51: M199-205, 1996.
- 595 35. **Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, and Behling C.**  
596 Prevalence of fatty liver in children and adolescents. *Pediatrics* 118: 1388-1393, 2006.
- 597 36. **Sigal RJ, Kenny GP, Boule NG, Wells GA, Prud'homme D, Fortier M, Reid RD,**  
598 **Tulloch H, Coyle D, Phillips P, Jennings A, and Jaffey J.** Effects of aerobic training,  
599 resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. *Ann Intern*  
600 *Med* 147: 357-369, 2007.
- 601 37. **Tanner JM.** Growth and maturation during adolescence. *Nutr Rev* 39: 43-55, 1981.
- 602 38. **Treuth MS, Hunter GR, Figueroa-Colon R, and Goran MI.** Effects of strength  
603 training on intra-abdominal adipose tissue in obese prepubertal girls. *Med Sci Sports Exerc* 30:  
604 1738-1743, 1998.
- 605 39. **van der Heijden GJ, Wang ZJ, Chu ZD, Sauer PJ, Haymond MW, Rodriguez LM,**  
606 **and Sunehag AL.** A 12-week aerobic exercise program reduces hepatic fat accumulation and  
607 insulin resistance in obese, Hispanic adolescents. *Obesity (Silver Spring)* 18: 384-390, 2010.
- 608 40. **Weiss R, Dufour S, Taksali SE, Tamborlane WV, Petersen KF, Bonadonna RC,**  
609 **Boselli L, Barbetta G, Allen K, Rife F, Savoye M, Dziura J, Sherwin R, Shulman GI, and**  
610 **Caprio S.** Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin  
611 resistance, and altered myocellular and abdominal fat partitioning. *Lancet* 362: 951-957, 2003.
- 612 41. **Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K,**  
613 **Lopes M, Savoye M, Morrison J, Sherwin RS, and Caprio S.** Obesity and the metabolic  
614 syndrome in children and adolescents. *N Engl J Med* 350: 2362-2374, 2004.
- 615  
616  
617



618 **Table 1.** Subject characteristics at baseline  
619

	Control <i>n</i> =12	Aerobic Exercise <i>n</i> = 16	Resistance Exercise <i>n</i> = 16	<i>P</i>	<i>P</i> §
Black/White ( <i>n</i> )	9/3	9/7	12/4	0.438	
Puberty, III/IV/V ( <i>n</i> )	0/1/11	0/3/13	0/2/14	0.719	
<b>Anthropometric</b>					
Age (years)	15.0 ± 2.2	14.6 ± 1.9	14.8 ± 1.9	0.819	
Body weight (kg)	93.3 ± 13.1	88.9 ± 16.3	97.1 ± 16.0	0.326	
BMI (kg/m <sup>2</sup> )	35.3 ± 4.0	32.9 ± 3.8	36.4 ± 3.8 †	0.049	
Waist (cm)	110.9 ± 8.4	106.5 ± 11.1	115.3 ± 11.7	0.079	
<b>MRI *</b>					
Total AT (kg)	48.1 ± 9.4	43.3 ± 11.0	50.4 ± 11.5	0.186	0.760
Total body fat (%)	51.3 ± 3.5	47.8 ± 4.2	51.5 ± 4.7 †	0.035	0.298
Skeletal muscle (kg)	22.7 ± 2.7	23.0 ± 4.2	23.2 ± 3.1	0.928	0.206
VAT (cm <sup>2</sup> )	58.6 ± 23.7	51.8 ± 23.3	63.2 ± 23.6	0.407	0.576
ASAT (cm <sup>2</sup> )	538.2 ± 117.9	444.5 ± 155.0	536.8 ± 127.9	0.114	0.545
Intrahepatic lipid (%)	3.0 ± 5.4	2.2 ± 3.3	2.0 ± 1.3	0.738	0.530
<b>CT at mid-thigh</b>					
IMAT (cm <sup>2</sup> )	59.3 ± 13.3	53.8 ± 24.7	58.3 ± 18.9	0.736	0.376
Muscle attenuation (HU)	52.0 ± 1.6	52.2 ± 2.5	50.7 ± 3.4	0.231	0.526
<b>Metabolic</b>					
Fasting glucose (mg/dl)	97.0 ± 6.7	93.2 ± 5.9	94.4 ± 6.8	0.309	0.410
Fasting insulin (μU/ml)	31.1 ± 15.3	28.6 ± 16.5	45.8 ± 22.0 †	0.026	0.082
Fasting HGP (mg/kg/min)	1.89 ± 0.38	1.87 ± 0.29	1.79 ± 0.44	0.165	0.206
Fasting Hepatic insulin sensitivity (mg/kg/min per μU/ml <sup>-1</sup> )	22.9 ± 14.4	24.2 ± 12.2	16.5 ± 10.5	0.188	0.101
Glucose at 2 hr (mg/dl)	121.7 ± 28.5	120.7 ± 19.8	117.7 ± 15.5	0.865	0.797
Insulin at 2 hr (μU/ml)	104.1 ± 102.8	153.6 ± 143.7	207.0 ± 170.8	0.188	0.171
Glucose AUC (mg·min/dl)	15283.9 ± 3044.2	14818.1 ± 2363.7	14748.0 ± 1334.9	0.807	0.564
Insulin AUC (μU·min/ml)	15781.8 ± 8121.4	17038.0 ± 14281.2	28605.9 ± 17643.8 ‡	0.035	0.077
Insulin sensitivity (mg/kg/min per μU/ml)	2.7 ± 1.3	2.8 ± 1.3	1.8 ± 0.8 †	0.034	0.101
Insulin sensitivity (mg/kgFFM/min per μU/ml)	5.1 ± 2.5	5.1 ± 2.4	3.4 ± 1.6	0.060	0.100
<b>Fitness</b>					
VO <sub>2peak</sub> (ml/kg/min)	23.9 ± 3.0	28.5 ± 3.8	24.3 ± 4.3 †	0.004	0.090
Muscular strength index	1.0 ± 0.2	1.1 ± 0.2	1.0 ± 0.2	0.897	0.906

620 Values are means (SD). \* *n*=15 in the aerobic group.

621 † Different from the aerobic exercise group (*P*<0.05). ‡ Different from the control group (*P*=0.06).

622 § ANCOVA adjusting for BMI and race. AT, adipose tissue; VAT, visceral AT; ASAT, abdominal subcutaneous AT

623 IMAT, intermuscular AT; HGP, hepatic glucose production; AUC, area under the curve.

624 **Table 2.** Absolute changes in total and regional fat distribution and fitness after 3 months

	Control ( <i>n</i> =8/ITT=12)	Aerobic Exercise ( <i>n</i> =14/ITT =16)		Resistance Exercise ( <i>n</i> =14/ITT =16)	
	Mean ± SE	Mean ± SE	<i>P</i>	Mean ± SE	<i>P</i>
	Intent-to-Treat Analysis ( <i>n</i> = 44)				
Body weight (kg)	0.13 ± 1.10	-1.31 ± 1.43	0.360	-0.31 ± 1.38	0.822
BMI (kg/m <sup>2</sup> )	-0.03 ± 0.44	-0.46 ± 0.58	0.430	-0.28 ± 0.54	0.608
Waist (cm)	-0.25 ± 1.30	-2.48 ± 1.67	0.137	-1.82 ± 1.66	0.271
Total AT (kg)	0.70 ± 1.01	-2.38 ± 1.25	0.058	-2.23 ± 1.21	0.065
Total body fat (%)	0.10 ± 0.66	-1.70 ± 0.85	0.046	-1.63 ± 0.78	0.035
Skeletal muscle (kg)	0.21 ± 0.51	0.13 ± 0.63	0.834	0.61 ± 0.61	0.317
VAT (cm <sup>2</sup> )	5.87 ± 6.17	-15.68 ± 7.64	0.041	-4.52 ± 7.23	0.532
ASAT (cm <sup>2</sup> )	-2.93 ± 16.3	-7.78 ± 20.42	0.703	-14.36 ± 19.61	0.464
Intrahepatic lipid (%)	0.75 ± 0.57	-1.70 ± 0.74	0.022	-0.70 ± 0.69	0.308
IMAT (cm <sup>2</sup> )	1.1 ± 3.4	-13.5 ± 4.2	0.001	-10.9 ± 4.2	0.010
Muscle attenuation (HU)	0.41 ± 0.42	0.13 ± 0.53	0.811	0.23 ± 0.54	0.678
VO <sub>2peak</sub> (ml/kg/min)	-0.21 ± 1.42	4.91 ± 1.82	0.007	2.87 ± 1.71	0.095
Muscular strength index	0.07 ± 0.09	0.08 ± 0.11	0.481	0.45 ± 0.11	<0.0001
	Per-Protocol Analysis ( <i>n</i> = 36)				
Body weight (kg)	0.28 ± 1.1	-1.44 ± 0.84	0.307	-0.44 ± 0.83	0.748
BMI (kg/m <sup>2</sup> )	0.02 ± 0.44	-0.52 ± 0.57	0.369	-0.34 ± 0.54	0.540
Waist (cm)	-0.37 ± 1.22	-2.39 ± 1.56	0.135	-1.72 ± 1.57	0.281
Total AT (kg)	0.67 ± 0.96	-2.33 ± 1.21	0.063	-2.20 ± 1.18	0.072
Total body fat (%)	0.08 ± 0.63	-1.66 ± 0.81	0.050	-1.61 ± 0.76	0.041
Skeletal muscle (kg)	0.20 ± 0.49	0.16 ± 0.61	0.798	0.63 ± 0.60	0.297
VAT (cm <sup>2</sup> )	4.91 ± 5.79	-15.40 ± 7.29	0.043	-4.28 ± 7.03	0.547
ASAT (cm <sup>2</sup> )	-3.2 ± 15.70	-6.92 ± 19.77	0.729	-13.69 ± 19.14	0.480
Intrahepatic lipid (%)	0.55 ± 0.56	-1.59 ± 0.70	0.031	-0.59 ± 0.69	0.398
IMAT (cm <sup>2</sup> )	0.8 ± 3.3	-13.3 ± 4.13	0.003	-10.9 ± 4.2	0.014
Muscle attenuation (HU)	0.39 ± 0.42	0.15 ± 0.52	0.766	0.22 ± 0.53	0.682
VO <sub>2peak</sub> (ml/kg/min)	-0.43 ± 1.36	5.17 ± 1.78	0.007	3.10 ± 1.69	0.077
Muscular strength index	0.07 ± 0.09	0.08 ± 0.11	0.459	0.45 ± 0.11	0.0003

625 Values are imputed means (SE).

626 Change values for the intervention groups are the difference as compared to control with adjustment for  
627 baseline values as assessed using ANCOVA.

628 *P*-values as compared to the control group.

629 ITT, Intent-to-treat; AT, adipose tissue; VAT, visceral AT; ASAT, abdominal subcutaneous AT; IMAT,  
630 intermuscular AT; HU, Hounsfield unit.

631

632 **Table 3.** Absolute changes in metabolic variables after 3 months

	Control ( <i>n</i> =8/ITT=12)	Aerobic Exercise ( <i>n</i> =14/ITT=16)	<i>P</i>	Resistance Exercise ( <i>n</i> =14/ITT=16)	<i>P</i>
	Mean ± SE	Mean ± SE		Mean ± SE	
Intent-to-Treat Analysis ( <i>n</i> = 44)					
Fasting glucose (mg/dl)	1.35 ± 2.03	-2.11 ± 2.64	0.424	0.61 ± 2.54	0.811
Fasting insulin (μU/ml)	0.07 ± 3.34	-7.62 ± 4.33	0.079	-1.29 ± 4.37	0.768
Fasting HGP (mg/kg/min)	-0.09 ± 0.16	0.32 ± 0.20	0.120	0.14 ± 0.20	0.491
Hepatic insulin sensitivity (mg/kg/min per μU/ml <sup>-1</sup> )	0.87 ± 3.17	-0.04 ± 4.11	0.992	-6.96 ± 3.97	0.080
Glucose at 2 hr (mg/dl)	5.47 ± 6.39	-3.01 ± 8.0	0.706	-2.01 ± 8.12	0.805
Insulin at 2 hr (μU/ml)	15.17 ± 39.48	-60.66 ± 49.62	0.222	9.25 ± 50.53	0.855
Glucose AUC (mg·min/dl)	12.95 ± 490.55	62.69 ± 630.72	0.921	-126.12 ± 613.69	0.837
Insulin AUC (μU·min/ml)	-837.00 ± 2927.61	-4087.57 ± 3715.96	0.272	-2441.82 ± 3834.03	0.524
Insulin sensitivity (mg/kg/min per μU/ml)	-0.46 ± 0.21	0.92 ± 0.27	0.0007	0.03 ± 0.27	0.902
Insulin sensitivity (mg/kgFFM/min per μU/ml)	-0.79 ± 0.35	1.43 ± 0.44	0.0011	-0.13 ± 0.45	0.767
Per-Protocol Analysis ( <i>n</i> = 36)					
Fasting glucose (mg/dl)	1.60 ± 2.01	-2.35 ± 2.53	0.361	0.38 ± 2.52	0.882
Fasting insulin (μU/ml)	-0.05 ± 3.34	-8.03 ± 4.19	0.064	-1.65 ± 4.3	0.707
Fasting HGP (mg/kg/min)	-0.09 ± 0.156	2.92 ± 0.20	0.146	0.12 ± 1.96	0.556
Hepatic insulin sensitivity (mg/kg/min per μU/ml <sup>-1</sup> )	1.39 ± 3.12	-0.25 ± 3.96	0.951	-7.22 ± 3.95	0.077
Glucose at 2 hr (mg/dl)	4.74 ± 6.24	-2.56 ± 7.80	0.745	-2.00 ± 7.97	0.803
Insulin at 2 hr (μU/ml)	10.8 ± 38.8	-57.70 ± 48.42	0.242	9.49 ± 49.74	0.850
Glucose AUC (mg·min/dl)	43.44 ± 485.72	7.47 ± 608.45	0.990	-180.29 ± 609.69	0.769
Insulin AUC (μU·min/ml)	-739.76 ± 2921.24	-4418.58 ± 3590.20	0.227	-2764.87 ± 3820.03	0.475
Insulin sensitivity (mg/kg/min per μU/ml)	-0.49 ± 0.21	1.10 ± 0.07	0.0002	0.07 ± 0.26	0.793
Insulin sensitivity (mg/kgFFM/min per μU/ml)	-0.78 ± 0.34	1.44 ± 0.43	0.0021	-0.13 ± 0.44	0.778

633 Values are imputed means (SE).

634 Change values for the intervention groups are the difference as compared to control with adjustment for baseline values as assessing using ANCOVA.

635 values as assessing using ANCOVA.

636 *P*-values as compared to the control group.

637 HGP: hepatic glucose production

638

639 **FIGURE LEGENDS**

640

641 **FIGURE 1.** Participant flow diagram. All subjects assigned to each group (including subjects who  
642 discontinued the study) were included in intent-to-treat analyses.

643

644 **FIGURE 2.** Absolute change in hepatic insulin sensitivity and peripheral insulin sensitivity for each  
645 intervention group. Values for the control group are imputed means (SE). Change values for the  
646 intervention groups are the difference as compared to control with adjustment for baseline values as  
647 assessing using ANCOVA. \*  $P < 0.001$  as compared to the control group.

648

**Figure 1**




Figure 2

